Imaging Inflamed Plaque in Arteries With a PET Tracer
Tests florbetaben PET imaging for inflamed artery plaque after heart events or stroke.
Plain-language title generated from the registry record
Registry title: Florbetaben for Imaging of Vascular Amyloid
Key facts
- Where
- Ottawa, CanadaSee the site
Where in Canada
- University of Ottawa Heart InstituteOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Heart Institute Research Corporation
- Trial code
- NCT06091319
- Record updated
- 8 September 2026
- Original description
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.Read full original descriptionShow less
Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.
Inclusion: suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI; stable symptoms and hemodynamics; age >/= 18 years; given informed consent.
Exclusion: severe valve disease requiring intervention; decompensated heart failure; Florbetaben allergy; glomerular filtration rate (GFR) <50 ml/min/1.72m2; Exclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR <60, will not undergo CTA but will have PET/CT; a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist; severe LV dysfunction (EF<30%); pregnancy (all women of child bearing potential will have a negative BHCG test; breastfeeding; women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception; unable to give informed consent.